Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13228621 | 0.81 | NPC1 (0.31) | NPC1LMNATP53RAB9ASMN1; SMN2 | |
| SCHEMBL12384343 | 0.77 | CNR2 (0.31) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22217015 | 0.76 | — | — | |
| SCHEMBL19135501 | 0.75 | ESR1 (0.34) | — | |
| SCHEMBL21362058 | 0.73 | — | — | |
| SCHEMBL15199502 | 0.69 | NPC1 (0.33) | NPC1LMNATP53RAB9ASMN1; SMN2 | |
| SCHEMBL1106198 | 0.69 | NPC1 (0.33) | NPC1LMNATP53RAB9ASMN1; SMN2 | |
| SCHEMBL22140382 | 0.67 | NPC1 (0.32) | NPC1LMNATP53RAB9ASMN1; SMN2 | |
| SCHEMBL22140288 | 0.67 | NPC1 (0.32) | NPC1LMNATP53RAB9ASMN1; SMN2 | |
| SCHEMBL22140146 | 0.67 | NPC1 (0.32) | NPC1LMNATP53RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330245-A1 | ANTIBODY-EXATECAN CONJUGATES | SYNAFFIX B.V. (NL) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330245-A1 | ANTIBODY-EXATECAN CONJUGATES | ERBB3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IL23R | NPC1 4057/4885LMNA 2021/4885TP53 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.